These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 30027649)

  • 21. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
    Imberti D; Mastroiacovo D
    Intern Emerg Med; 2017 Aug; 12(5):561-563. PubMed ID: 28647891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2018 Jan; 107(3):167-168. PubMed ID: 29382267
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion.
    Warden BA; MacKay J; Jafari M; Willman A; Stecker EC
    J Am Heart Assoc; 2018 Nov; 7(22):e010854. PubMed ID: 30571504
    [No Abstract]   [Full Text] [Related]  

  • 25. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
    Robert-Ebadi H; Righini M
    Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
    [No Abstract]   [Full Text] [Related]  

  • 26. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
    Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
    Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
    Howard LS
    Expert Rev Respir Med; 2018 May; 12(5):387-402. PubMed ID: 29542359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
    Fanikos J; Burnett AE; Mahan CE; Dobesh PP
    Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New anticoagulants in the prevention and treatment of venous thromboembolism].
    Keltai M; Keltai K
    Orv Hetil; 2011 Jun; 152(25):983-92. PubMed ID: 21642050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug Treatment of Venous Thromboembolism in the Elderly.
    Boey JP; Gallus A
    Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer-associated thrombosis - treatment and prevention with direct oral factor Xa inhibitors.
    Grilusová K; Bolek T; Škorňová I; Staško J; Samoš M; Mokáň M
    Klin Onkol; 2021; 34(4):283-290. PubMed ID: 34905929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI; Jaffer IH
    Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [State of the art: Direct oral anticoagulants and transfusion].
    Martin AC; Godier A; Smadja DM; Mauge L; Fischer AM
    Transfus Clin Biol; 2017 Sep; 24(3):154-159. PubMed ID: 28673500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
    Krumme AA; Pawar A; Schneeweiss S; Glynn RJ; Choudhry NK; Kulldorff M; Ortiz AS; Avorn J; Gagne JJ
    J Comp Eff Res; 2018 Jan; 7(1):57-66. PubMed ID: 29264930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
    Squizzato A; Lussana F; Cattaneo M
    Thromb Haemost; 2015 Aug; 114(2):237-44. PubMed ID: 25946985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation.
    Aronow WS; Shamliyan TA
    Am J Ther; 2019; 26(6):e679-e703. PubMed ID: 30461433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct oral anticoagulants (DOACs).
    Vazquez S; Rondina MT
    Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.